Moreover, SREBP-1c is a major transcription factor regulating lipogenesis and its downstream targets FAS, ACC, and SCD, and its activation aggravates the symptoms of NAFLD [47]. The gene discussed is FAS; the disease is metabolic dysfunction-associated steatotic liver disease.